CRY2

Across TCGA pan-cancer cohorts, CRY2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CRY2 data layer compared with 28 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher CRY2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CRY2 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

LUAD, PDAC, and GBM are the cancer types where CRY2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Tertile	II,III,IV	0.719	0.963	.005	22	view →
PDAC	OS	Median	II,III,IV	0.678	0.213	.006	19	view →
GBM	DFS	Tertile	All	0.228	0.417	.026	2	view →
CCRCC	DFS	Tertile	All	1.000	0.497	.049	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CRY2–LUAD (DFS)

Open the LUAD breakdown →